Related Experiment Videos
The hypouricemic effect of o,p'-DDD.
The American Journal of the Medical Sciences
|September 1, 1979
Summary
The drug o,p-DDD effectively lowers serum uric acid levels in patients by increasing renal clearance, not by affecting production. This new compound offers a novel approach to managing hyperuricemia.
Area of Science:
- Pharmacology
- Nephrology
- Endocrinology
Background:
- Hyperuricemia is a condition characterized by elevated serum uric acid levels.
- Current treatments for hyperuricemia may have limitations or side effects.
- Identifying novel agents for managing uric acid levels is of clinical interest.
Purpose of the Study:
- To investigate the hypouricemic effect of o,p'-DDD.
- To determine the mechanism by which o,p'-DDD affects serum uric acid concentration.
- To explore o,p'-DDD as a potential new therapeutic agent.
Main Methods:
- Administration of o,p'-DDD orally to eight normouricemic patients.
- Dosage ranged from 1 to 7 grams daily for 5 to 42 days.
- Monitoring of serum and urinary uric acid levels.
Main Results:
- o,p'-DDD significantly lowered serum uric acid concentration by 21-53% (average 39%).
- The hypouricemic effect was observed within 5-10 days.
- Urinary uric acid excretion remained unchanged, indicating increased renal clearance rather than altered production.
Conclusions:
- o,p'-DDD demonstrates a potent hypouricemic effect in humans.
- The mechanism involves enhanced renal clearance of uric acid.
- o,p'-DDD represents a new class of chemical compounds with potential as hypouricemic agents.